-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga·05/28/2026 12:58:55
Listen to the news
Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Outperform rating and announces Price Target of $35.